Technical Analysis for APLT - Applied Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 4.74 | -1.86% | -0.09 |
APLT closed down 1.86 percent on Thursday, April 18, 2024, on 35 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Wide Bands | Range Expansion | -1.86% | |
Oversold Stochastic | Weakness | -1.86% | |
Stochastic Buy Signal | Bullish | -7.96% | |
Wide Bands | Range Expansion | -7.96% | |
Oversold Stochastic | Weakness | -7.96% | |
Lower Bollinger Band Walk | Weakness | -6.32% | |
Wide Bands | Range Expansion | -6.32% |
Alert | Time |
---|---|
Possible Inside Day | about 13 hours ago |
Up 3% | about 17 hours ago |
Up 2% | about 17 hours ago |
60 Minute Opening Range Breakout | about 17 hours ago |
Up 1% | about 17 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Cardiomyopathy Myopathy Retinopathy Peripheral Neuropathy Preclinical Stage Product Stage Products Diabetic Peripheral Neuropathy Lactose Novel Products Preclinical Stage Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Cardiomyopathy Myopathy Retinopathy Peripheral Neuropathy Preclinical Stage Product Stage Products Diabetic Peripheral Neuropathy Lactose Novel Products Preclinical Stage Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.39 |
52 Week Low | 0.9283 |
Average Volume | 2,041,088 |
200-Day Moving Average | 3.05 |
50-Day Moving Average | 5.61 |
20-Day Moving Average | 5.91 |
10-Day Moving Average | 5.28 |
Average True Range | 0.46 |
RSI (14) | 31.97 |
ADX | 21.29 |
+DI | 18.36 |
-DI | 28.03 |
Chandelier Exit (Long, 3 ATRs) | 6.02 |
Chandelier Exit (Short, 3 ATRs) | 6.02 |
Upper Bollinger Bands | 7.33 |
Lower Bollinger Band | 4.49 |
Percent B (%b) | 0.09 |
BandWidth | 47.99 |
MACD Line | -0.27 |
MACD Signal Line | -0.08 |
MACD Histogram | -0.1886 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.19 | ||||
Resistance 3 (R3) | 5.23 | 5.11 | 5.11 | ||
Resistance 2 (R2) | 5.11 | 5.00 | 5.09 | 5.09 | |
Resistance 1 (R1) | 4.93 | 4.93 | 4.87 | 4.89 | 5.06 |
Pivot Point | 4.81 | 4.81 | 4.79 | 4.80 | 4.81 |
Support 1 (S1) | 4.63 | 4.70 | 4.57 | 4.59 | 4.42 |
Support 2 (S2) | 4.51 | 4.63 | 4.50 | 4.39 | |
Support 3 (S3) | 4.33 | 4.51 | 4.37 | ||
Support 4 (S4) | 4.29 |